Plain-English translation of NCT06826079 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether sorbitol, an oral sugar supplement, can make chemotherapy and immunotherapy work better together for advanced stomach cancer. About 86 people with locally advanced stomach or gastroesophageal junction cancer will receive either the new combination (sorbitol plus standard chemotherapy and a PD-1 inhibitor called tirellizumab) or the standard treatment alone (chemotherapy and tirellizumab). The study aims to see if adding this medication improves how well the cancer responds before surgery.
Current treatments for advanced stomach cancer help some patients, but doctors are looking for ways to make them more effective. This trial explores whether this medication, which may work through the body's metabolism and immune system, could boost the effects of existing chemotherapy and immunotherapy approaches.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new treatment combination or the standard treatment. Before treatment starts, you'll have screening tests including blood work, imaging scans, and tissue testing. Then you'll receive 3 cycles of treatment (each cycle is 3 weeks apart), which includes chemotherapy, immunotherapy, and either the oral sugar supplement or placebo depending on your group. After completing the treatment cycles, you'll have surgery to remove the cancer, followed by additional supportive therapy and regular follow-up visits to monitor your health and how well the treatment worked.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China